Gamida Cell: Q2 Earnings Insights

Shares of Gamida Cell GMDA moved higher by 1.6% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 15.91% over the past year to ($0.37), which missed the estimate of ($0.30).

Revenue of $0 unchanged by 0.00% from the same period last year, which missed the estimate of $140,000.

Looking Ahead

Gamida Cell hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 11, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/uz9dm8st

Price Action

52-week high: $7.70

52-week low: $2.60

Price action over last quarter: down 16.98%

Company Description

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.